

**From:** [Trials](#)  
**To:** [Snedden, Sheridan](#); [Paulraj, Christopher](#); [Hulse, Tina](#)  
**Cc:** [Trials](#)  
**Subject:** FW: IPR2016-01127, 01128, 01129, 01130, 01131, and 01132  
**Date:** Thursday, March 30, 2017 6:32:36 AM

---

Please see below

Thanks  
Andrew

---

**From:** Dorothy Whelan [mailto:whelan@fr.com]  
**Sent:** Thursday, March 30, 2017 9:22 AM  
**To:** Trials <Trials@USPTO.GOV>  
**Cc:** sparmelee@wsgr.com; mrosato@wsgr.com; jmills@wsgr.com; IPR13351-0008IP1 <IPR13351-0008IP1@fr.com>; PTAB Inbound <PTABInbound@fr.com>; Michael Kane <kane@fr.com>; dmazochi@rmmslegal.com; jpolivick@rmmslegal.com; pabbott@rmmslegal.com; gspeier@carlsoncaspers.com; mschuman@carlsoncaspers.com; mdzwonczyk@sughrue.com; akokabi@sughrue.com; Ribar, Travis B. <tribar@sughrue.com>; PCurtin@rmmslegal.com  
**Subject:** RE: IPR2016-01127, 01128, 01129, 01130, 01131, and 01132

Patent Owner does not intend to file Preliminary Responses to the Teva and Akorn Petitions.

Regards,  
Dorothy Whelan  
Counsel for Patent Owner, Allergan, Inc.

---

**From:** Trials [mailto:Trials@USPTO.GOV]  
**Sent:** Wednesday, March 29, 2017 11:50 AM  
**To:** Trials <Trials@USPTO.GOV>; Dorothy Whelan <whelan@fr.com>  
**Cc:** sparmelee@wsgr.com; mrosato@wsgr.com; jmills@wsgr.com; IPR13351-0008IP1 <IPR13351-0008IP1@fr.com>; PTAB Inbound <PTABInbound@fr.com>; Michael Kane <kane@fr.com>; dmazochi@rmmslegal.com; jpolivick@rmmslegal.com; pabbott@rmmslegal.com; gspeier@carlsoncaspers.com; mschuman@carlsoncaspers.com; mdzwonczyk@sughrue.com; akokabi@sughrue.com; Ribar, Travis B. <tribar@sughrue.com>; PCurtin@rmmslegal.com  
**Subject:** RE: IPR2016-01127, 01128, 01129, 01130, 01131, and 01132

Counsel,

Following our telephone conference yesterday, the panel seeks further clarification from Patent Owner regarding whether it intends to file Preliminary Responses to the Teva and Akorn Petitions, or if Patent Owner waives those Preliminary Responses.

Patent Owner, please respond to this email by close of business on Monday, April 3, 2017.

Regards,

Andrew Kellogg,  
Supervisory Paralegal  
Patent Trial and Appeal Board  
USPTO  
[andrew.kellogg@uspto.gov](mailto:andrew.kellogg@uspto.gov)  
Direct: 571-272-5366

---

**From:** Trials  
**Sent:** Tuesday, March 28, 2017 10:12 AM  
**To:** Dorothy Whelan <whelan@fr.com>; Trials <Trials@USPTO.GOV>  
**Cc:** sparmelee@wsgr.com; mrosato@wsgr.com; jmills@wsgr.com; IPR13351-0008IP1 <IPR13351-0008IP1@fr.com>; PTAB Inbound <PTABInbound@fr.com>; Michael Kane <kane@fr.com>; dmazochi@rmmslegal.com; jpolivick@rmmslegal.com; pabbott@rmmslegal.com; gspeier@carlsoncaspers.com; mschuman@carlsoncaspers.com; mdzwonczyk@sughrue.com; akokabi@sughrue.com; Ribar, Travis B. <tribar@sughrue.com>; PCurtin@rmmslegal.com  
**Subject:** RE: IPR2016-01127, 01128, 01129, 01130, 01131, and 01132

Counsel,

The call will be today at 12:00 pm EST. The dial in number is 877-476-3810 and the passcode is 8984275.

Regards,

Andrew Kellogg,  
Supervisory Paralegal

Patent Trial and Appeal Board  
USPTO  
[andrew.kellogg@uspto.gov](mailto:andrew.kellogg@uspto.gov)  
Direct: 571-272-5366

---

**From:** Dorothy Whelan [<mailto:whelan@fr.com>]  
**Sent:** Monday, March 27, 2017 5:10 PM  
**To:** Trials <[Trials@USPTO.GOV](mailto:Trials@USPTO.GOV)>  
**Cc:** [sparmelee@wsgr.com](mailto:sparmelee@wsgr.com); [mrosato@wsgr.com](mailto:mrosato@wsgr.com); [jmills@wsgr.com](mailto:jmills@wsgr.com); IPR13351-0008IP1 <[IPR13351-0008IP1@fr.com](mailto:IPR13351-0008IP1@fr.com)>; PTAB Inbound <[PTABInbound@fr.com](mailto:PTABInbound@fr.com)>; Michael Kane <[kane@fr.com](mailto:kane@fr.com)>; [dmazzoichi@rmmslegal.com](mailto:dmazzoichi@rmmslegal.com); [jpolivick@rmmslegal.com](mailto:jpolivick@rmmslegal.com); [pabbott@rmmslegal.com](mailto:pabbott@rmmslegal.com); [gspeier@carlsoncaspers.com](mailto:gspeier@carlsoncaspers.com); [mschuman@carlsoncaspers.com](mailto:mschuman@carlsoncaspers.com); [mdzwonczyk@sughrue.com](mailto:mdzwonczyk@sughrue.com); [akokabi@sughrue.com](mailto:akokabi@sughrue.com); Ribar, Travis B. <[tribar@sughrue.com](mailto:tribar@sughrue.com)>; [PCurtin@rmmslegal.com](mailto:PCurtin@rmmslegal.com)  
**Subject:** RE: IPR2016-01127, 01128, 01129, 01130, 01131, and 01132

Dear Board: Could you please advise whether the panel is available for a teleconference on Tuesday, March 28 at 12 pm EST for a teleconference? Thank you for your consideration.

Regards,  
Dorothy Whelan  
Counsel for Patent Owner, Allergan, Inc.

---

**From:** Dorothy Whelan  
**Sent:** Wednesday, March 22, 2017 6:50 AM  
**To:** Trials <[Trials@USPTO.GOV](mailto:Trials@USPTO.GOV)>  
**Cc:** [sparmelee@wsgr.com](mailto:sparmelee@wsgr.com); [mrosato@wsgr.com](mailto:mrosato@wsgr.com); [jmills@wsgr.com](mailto:jmills@wsgr.com); IPR13351-0008IP1 <[IPR13351-0008IP1@fr.com](mailto:IPR13351-0008IP1@fr.com)>; PTAB Inbound <[PTABInbound@fr.com](mailto:PTABInbound@fr.com)>; Michael Kane <[kane@fr.com](mailto:kane@fr.com)>; [dmazzoichi@rmmslegal.com](mailto:dmazzoichi@rmmslegal.com); [jpolivick@rmmslegal.com](mailto:jpolivick@rmmslegal.com); [pabbott@rmmslegal.com](mailto:pabbott@rmmslegal.com); [gspeier@carlsoncaspers.com](mailto:gspeier@carlsoncaspers.com); [mschuman@carlsoncaspers.com](mailto:mschuman@carlsoncaspers.com); [mdzwonczyk@sughrue.com](mailto:mdzwonczyk@sughrue.com); [akokabi@sughrue.com](mailto:akokabi@sughrue.com); Ribar, Travis B. <[tribar@sughrue.com](mailto:tribar@sughrue.com)>; [PCurtin@rmmslegal.com](mailto:PCurtin@rmmslegal.com)  
**Subject:** Re: IPR2016-01127, 01128, 01129, 01130, 01131, and 01132

Dear Board: The parties have conferred and propose Tuesday, March 28 at 12 pm eastern standard time for a teleconference.

Regards  
Dorothy Whelan  
Counsel for patent owner, Allergan, Inc

Sent from my iPhone

On Mar 20, 2017, at 3:34 PM, Trials <[Trials@USPTO.GOV](mailto:Trials@USPTO.GOV)> wrote:

Counsel,

The panel requests a teleconference among Patent Owner Allergan, Inc. and Petitioners Famy Care Limited ("FCL") and Mylan Pharmaceuticals to discuss FCL's motion for joinder filed in IPR2017-00566, -00567, -00568, -00569, -00570, and -00571. The panel is inclined to grant the motions for joinder, but would like to discuss various procedural issues with the parties, including the case schedule and proposals for supplemental briefing, if any. Petitioners Teva Pharmaceuticals USA, Inc. and Akorn, Inc., who have also filed motions for joinder, may join the call if they would like, but their attendance is not required.

The panel is available on Friday, March 24, at 1 pm ET. Should the parties not be available at this time, the panel requests that the parties confer and propose a time between 12 PM and 2 PM ET on any day between March 27<sup>th</sup> to March 31<sup>st</sup>.

Regards,

Andrew Kellogg,  
Supervisory Paralegal  
Patent Trial and Appeal Board  
USPTO  
[andrew.kellogg@uspto.gov](mailto:andrew.kellogg@uspto.gov)  
Direct: 571-272-5366

\*\*\*\*\*  
This email message is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Unauthorized use or disclosure is prohibited. If you are not the intended recipient, please contact the

sender by reply email and destroy all copies of the original message.  
\*\*\*\*\*

\*\*\*\*\*  
This email message is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized use or disclosure is prohibited. If you are not the intended recipient, please contact the sender by reply email and destroy all copies of the original message.  
\*\*\*\*\*